Extending Late-Stage Mesothelioma Survival with Light Energy

Research & Clinical Trials
Reading Time: 4 mins
Publication Date: 12/01/2016
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.

Asbestos.com is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at Asbestos.com

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us


"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating

How to Cite Asbestos.com’s Article


Povtak, T. (2022, December 16). Extending Late-Stage Mesothelioma Survival with Light Energy. Asbestos.com. Retrieved February 8, 2023, from https://www.asbestos.com/news/2016/12/01/extended-survival-late-stage-mesothelioma/


Povtak, Tim. "Extending Late-Stage Mesothelioma Survival with Light Energy." Asbestos.com, 16 Dec 2022, https://www.asbestos.com/news/2016/12/01/extended-survival-late-stage-mesothelioma/.


Povtak, Tim. "Extending Late-Stage Mesothelioma Survival with Light Energy." Asbestos.com. Last modified December 16, 2022. https://www.asbestos.com/news/2016/12/01/extended-survival-late-stage-mesothelioma/.

Thoracic surgeon Dr. Joseph Friedberg and his colleagues identified a subset of patients with pleural mesothelioma who achieved a median overall survival of 7.3 years — an impressive survival compared to the usual one-year prognosis.

The findings, which were published recently in The Annals of Thoracic Surgery, stemmed from a retrospective study that detailed significant progress in the fight against this incurable, asbestos-related cancer.

The study included 73 patients with epithelioid mesothelioma who were treated at the Penn Medicine Abramson Cancer Center, where Friedberg practiced before taking the role of director of the Mesothelioma and Thoracic Oncology Treatment and Research Center at the University of Maryland in 2015.

As part of their multidisciplinary treatment, Friedberg performed the aggressive pleurectomy/decortication (P/D) surgery, and they received intraoperative photodynamic therapy (PDT) and chemotherapy.

Among all participants, the median overall survival and disease-free survival was 3.0 and 1.2 years, respectively, almost double the typical prognosis for this disease.

But a subset of 19 patients without lymph node metastases showed a median progression-free and overall survival of 2.3 and 7.3 years, respectively.

“That was not anticipated, but [it’s] very encouraging,” Friedberg told Asbestos.com. “It jumps out at you.”

Photodynamic Therapy Is Just One Adjuvant Option

Friedberg said the results re-emphasized the importance of patient selection in determining eligibility and practicality for surgery. All cancer patients in the group were stage III or stage IV.

The results also emphasized the need for the randomized clinical trial currently ongoing at Abramson Cancer Center to determine how much of a role PDT plays in increasing survival times.

PDT, which a few cancer centers administer for mesothelioma, uses light energy to kill the tumor cells and is performed in conjunction with surgery. Prior to surgery, patients are given a drug that makes cells sensitive to certain wavelengths of light.

When the cancer cells are exposed to light, the combination of the drug and light causes a reaction that kills nearby cancer cells without harming healthy cells.

After the surgeon has finished removing all visible tumor cells, and with the chest still open, PDT is used to eliminate any remaining tumor cells left behind after surgery.

“Whether or not the photodynamic therapy contributed to the success is unclear at this point. We don’t know for sure,” he said. “That needs to be studied more to make a determination. More likely, the way you do the surgery is critically important.”

Friedberg does not utilize PDT at the University of Maryland when he performs the same aggressive surgery as he did at UPenn. Instead, he uses a post-surgery hyperthermic povidone-iodine wash of the internal chest cavity before surgical closure.

The intent — eliminating any microscopic tumor cells that surgery missed — is similar to PDT.

“Anecdotally, we’re getting good results with this,” he said. “But whether it really makes a big difference or not, you don’t know for sure. I do know the post-operative care is much easier this way.”

Povidone-iodine is a chemical compound and traditional antiseptic that often is used as a pre-surgical scrub. While it has shown positive results in several clinical trials involving other cancers, it has not been officially studied with mesothelioma.

The hope is that it prevents tumoral seeding, which occurs during surgery and slows any future metastasis.

Lung-Sparing Surgery for Mesothelioma

Friedberg believes that longer patient survival in the study could stem from his refinement of the meticulous P/D surgery, which leaves both lungs intact, as opposed to doing the extrapleural pneumonectomy (EPP), which removes an entire lung.

“These patients can still enjoy a pretty good quality of life after a very big operation,” he said. “I think having both lungs allows them to tolerate more aggressive treatment and contributes to overall survival.”

The selection of only patients with epithelioid mesothelioma also played a role in the study and often determines who is eligible for surgery. Epithelial mesothelioma accounts for 50-70 percent of all mesothelioma cases. It also is the most treatable type.

“I think we’re definitely making progress with this disease, but just not as fast as we’d like to see,” Friedberg said. “Surgery techniques are evolving. Adjuvant therapies, immunotherapies, are making a difference. We’re trying to get closer to making this more of a chronic disease than a uniformly fatal one.”

blue medical health symbol
Connect with a Mesothelioma Doctor
Find a Top Specialist Near You